$PLYX News

Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial

Why Polaryx Therapeutics Stock Is Surging On Thursday?

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards

Polaryx Therapeutics Says FDA Grants Fast Track Designation To PLX-200 For Treatment Of JNCL/CLN3 Disease, Krabbe Disease, And Sandhoff Disease

Polaryx Therapeutics Says FDA Grants Fast Track Designation To PLX-200 For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis

Maxim Group Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $10

What's Going On With Polaryx Therapeutics Stock Wednesday?

Polaryx shares are trading higher after the company announced it selected a contract research organization for SOTERIA to evaluate PLX-200, across four different LSDs.

Polaryx shares are trading higher after the company announced it selected a contract research organization for SOTERIA to evaluate PLX-200, across four different LSDs.

Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans

Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™

Polaryx Therapeutics Highlights Late-Breaking Presentation Of New Data For PLX-200, Investigational Therapy For Treatment Of Krabbe Disease At 22nd Annual WORLDSymposium

Polaryx Therapeutics Welcomes New Members of the Board of Directors

Polaryx to present late-breaker data related to Soteria ahead of trial

Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch

Polaryx To Present Late-Breaking SOTERIA Data At 22nd Annual WORLDSymposium Held Feb. 2-6

Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”

Polaryx Therapeutics Shares To Start Trading On Nasdaq Under Ticker Symbol PLYX On Feb. 2

Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq

Polaryx Therapeutics Approved For Nasdaq Listing